US 12,247,051 B2
PCV2 ORF2 protein variant and virus like particles composed thereof
Luis Alejandro Hernandez, Story City, IA (US); Christine Margaret Muehlenthaler, Ames, IA (US); Eric Martin Vaughn, Ames, IA (US); and Gregory Haiwick, Ankeny, IA (US)
Filed by Boehringer Ingelheim Animal Health USA Inc., Duluth, GA (US)
Filed on Nov. 21, 2023, as Appl. No. 18/516,237.
Application 18/516,237 is a continuation of application No. 17/215,636, filed on Mar. 29, 2021, granted, now 11,858,963.
Application 17/215,636 is a continuation of application No. 16/154,294, filed on Oct. 8, 2018, granted, now 10,961,281, issued on Mar. 30, 2021.
Application 16/154,294 is a continuation of application No. 15/295,053, filed on Oct. 17, 2016, granted, now 10,131,696, issued on Nov. 20, 2018.
Application 15/295,053 is a continuation of application No. 14/504,839, filed on Oct. 2, 2014, granted, now 9,505,808, issued on Nov. 29, 2016.
Claims priority of provisional application 61/885,871, filed on Oct. 2, 2013.
Prior Publication US 2024/0076321 A1, Mar. 7, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/005 (2006.01); A61K 39/12 (2006.01); C12N 7/00 (2006.01); C12P 21/02 (2006.01); A61K 39/00 (2006.01)
CPC C07K 14/005 (2013.01) [A61K 39/12 (2013.01); C12N 7/00 (2013.01); C12P 21/02 (2013.01); A61K 39/00 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/53 (2013.01); C12N 2710/14043 (2013.01); C12N 2750/10022 (2013.01); C12N 2750/10023 (2013.01); C12N 2750/10034 (2013.01); C12N 2750/10051 (2013.01); C12N 2799/026 (2013.01)] 4 Claims
OG exemplary drawing
 
1. A method of producing an immunogenic composition, comprising transfecting a cell with a plasmid, or an expression vector, wherein the plasmid or expression vector comprises a polynucleotide encoding:
a PCV2 ORF2 protein having
at amino acid position 59 an arginine residue or a lysine residue, and
at amino acid position 88 a proline residue, and
at amino acid position 151 a threonine residue, and
at amino acid position 206 an isoleucine residue, and
at amino acid position 232 an asparagine residue
and having at amino acid position 63 an amino acid residue other than an arginine residue or a lysine residue,
wherein the numbering of the amino acid positions refers to the amino acid sequence of wild type PCV2 ORF2 protein; and
wherein said immunogenic composition further contains a PCV2a ORF2 polypeptide.